愛污传媒

Skip to main content

Biogen cuts the price tag on its Alzheimer's drug in half

A vial and packaging for the drug Aduhelm.  (Biogen via AP) A vial and packaging for the drug Aduhelm. (Biogen via AP)
Share

Biogen is slashing the price of its Alzheimer's treatment in half months after it debuted to widespread criticism for an initial cost that could reach US$56,000 annually.

The drugmaker said Monday that it will cut the wholesale acquisition cost of the drug by about 50 per cent next month.

That means the annual cost for a person of average weight will amount to US$28,200.

The actual amount that person would pay will depend on factors like insurance coverage.

Biogen CEO Michel Vounatsos said in a prepared statement that too many patients were not being offered the drug due to "financial considerations," and their disease had progressed beyond the point where Aduhelm could help.

Aduhelm is the first in a line of new drugs that promise to do what no other Alzheimer's treatment has managed: slow the progress of the fatal brain-destroying disease, rather than just managing its symptoms.

The drug received FDA approval in June, and the agency later said it was appropriate for patients with mild symptoms or early-stage Alzheimer's.

But Aduhelm's debut has been slowed by concerns over the price and research behind the drug.

Some insurers have balked at paying for the drug, while medical centres across the country have been either slow to decide on using the drug or said they weren't planning to prescribe it for now.

Doctors have said concerns over the price were compounded by costs patients also would face for regular testing and scans needed to monitor their progress on Aduhelm.

Biogen said in June that it would not raise its price on the drug for four years, and the company often touted its financial assistance programs for patients.

RBC Capital Markets analyst Brian Abrahams said he was not surprised by Biogen's price cut. He said in a research note that the move was probably necessary and should "give Aduhelm its best opportunity for success."

The initial price was a key factor behind planned premium hikes for Medicare, the federal government's coverage program for people ages 65 and older and for the disabled.

Last month, Medicare announced one of the largest increases ever in its "Part B" monthly premium for outpatient care. It said it would raise the premium nearly US$22, from US$148.50 currently to US$170.10 starting in January.

The agency said about half of that hike was due to the need for a contingency fund to cover Aduhelm. Medicare is expected to be one main payers for the drug.

Aduhelm clears brain plaque thought to play a role in Alzheimer's disease, and U.S. regulators gave their approval based on study results showing the drug seemed likely to benefit patients. But they've asked for more research.

Biogen, which developed Aduhelm with Japan's Eisai Co., said last week the company expects to screen the first patients for their next study in May.

Researchers will aim to enroll about 1,300 people with early-stage Alzheimer's and expects to complete the research about four years after the study begins.

Concerns about the research behind the drug were a main reason the European Medicines Agency cited in refusing Aduhelm's marketing authorization last week.

Biogen said in October that Aduhelm had brought in only $300,000 in sales during its first full quarter on the market. The company attributed that figure partly to drug wholesalers drawing down inventory they had purchased the previous quarter.

Biogen also said Monday that it will start some cost-cutting measures that are expected to yield about US$500 million in annual savings, most of which will be realized next year.

The company said it was cutting costs in part because the slow debut of Aduhem was affecting its revenue.

Shares of Biogen Inc., based in Cambridge, Massachusetts, slipped US$1.07 to US$236.36 Monday morning while broader indexes fell.

The stock price had soared past US$425 in June after the FDA approval, but shares have since shed nearly half their value.

CTVNews.ca Top Stories

The identities have been released of the mother and daughter who were killed after a fire tore through a 160-year-old building in Old Montreal on Friday.

The sentencing of the man who pleaded guilty in the deadly hit-and-run in Kitsilano two years ago began on Friday.

A 30-year-old northwestern Ontario woman has been charged with arson following a structure fire Thursday night, police say.

Ontario Provincial Police have laid stunt charges against a driver caught speeding 75 km/h over the speed limit on Highway 417 in Ottawa's west end.

Travelling on a budget can be stressful, but there are ways you can ensure you're getting the best deal on flights as the holiday season approaches.

Local Spotlight

Chantal Kreviazuk is set to return to Winnipeg to mark a major milestone in her illustrious musical career.

From the beaches of Cannes to the bustling streets of New York City, a new film by a trio of Manitoba directors has toured the international film festival circuit to much pomp and circumstance.

A husband and wife have been on the road trip of a lifetime and have decided to stop in Saskatchewan for the winter.

The grave of a previously unknown Canadian soldier has been identified as a man from Hayfield, Man. who fought in the First World War.

A group of classic car enthusiasts donated hundreds of blankets to nursing homes in Nova Scotia.

Moving into the second week of October, the eastern half of Canada can expect some brisker fall air to break down from the north

What does New Westminster's t蓹m蓹sew虛tx史 Aquatic and Community Centre have in common with a historic 68,000-seat stadium in Beijing, an NFL stadium and the aquatics venue for the Paris Olympics? They've all been named among the world's most beautiful sports venues for 2024.

The last living member of the legendary Vancouver Asahi baseball team, Kaye Kaminishi, died on Saturday, Sept. 28, surrounded by family. He was 102 years old.

New data from Greater Vancouver and the Fraser Valley shows a surge in supply and drop in demand in the region's historically hot real estate market.